The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Observational cohort study of first-line bevacizumab combined with chemotherapy in metastatic colorectal cancer (HGCSG0802): Comparison of infusional FU/oxaliplatin(OX)+BV and oral FU/OX+BV.
 
Kazuteru Hatanaka
No Relationships to Disclose
 
Satoshi Yuki
Speakers' Bureau - Chugai Pharma; Yakult Pharmaceutical
 
Hiroshi Nakatsumi
No Relationships to Disclose
 
Hiraku Fukushima
No Relationships to Disclose
 
Hirohito Naruse
No Relationships to Disclose
 
Takashi Kato
No Relationships to Disclose
 
Takashi Meguro
No Relationships to Disclose
 
Michio Nakamura
No Relationships to Disclose
 
Ichiro Iwanaga
No Relationships to Disclose
 
Minoru Uebayashi
No Relationships to Disclose
 
Miki Tateyama
No Relationships to Disclose
 
Kazunori Eto
No Relationships to Disclose
 
Mineo Kudo
No Relationships to Disclose
 
Sosuke Kato
No Relationships to Disclose
 
Hiroyuki Okuda
No Relationships to Disclose
 
Susumu Sogabe
No Relationships to Disclose
 
Kencho Miyashita
No Relationships to Disclose
 
Yuh Sakata
Honoraria - Bristol-Myers Squibb; Daiichi Sankyo; Merck Serono; Otsuka; Taiho Pharmaceutical; Yakult Honsha
 
Yoshito Komatsu
Honoraria - Chugai Pharma; Yakult Pharmaceutical
Research Funding - Chugai Pharma (Inst)